NasdaqGM - Delayed Quote USD
Applied Therapeutics, Inc. (APLT)
At close: October 22 at 4:00 PM EDT
After hours: October 22 at 6:27 PM EDT
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Total Revenue
-333.00
9,993.00
--
--
--
--
Operating Expense
77,701.00
74,528.00
82,950.00
105,618.00
94,466.00
--
Operating Income
-78,034.00
-64,535.00
-82,950.00
-105,618.00
-94,466.00
--
Net Non Operating Interest Income Expense
1,959.00
1,372.00
685.00
555.00
559.00
--
Other Income Expense
-85,014.00
-56,600.00
-243.00
-521.00
-54.00
--
Pretax Income
-161,089.00
-119,763.00
-82,508.00
-105,584.00
-93,961.00
--
Net Income Common Stockholders
-161,089.00
-119,763.00
-82,508.00
-105,584.00
-93,961.00
--
Diluted NI Available to Com Stockholders
-161,089.00
-119,763.00
-82,508.00
-105,584.00
-93,961.00
--
Basic EPS
-1.43
-1.42
-2.18
-4.12
-4.28
--
Diluted EPS
-1.43
-1.42
-2.18
-4.12
-4.28
--
Basic Average Shares
117,677.21
84,244.49
37,825.43
25,598.18
21,966.33
--
Diluted Average Shares
117,677.21
84,244.49
37,825.43
25,598.18
21,966.33
--
Total Operating Income as Reported
-78,034.00
-64,535.00
-82,950.00
-105,618.00
-94,466.00
--
Total Expenses
77,701.00
74,528.00
82,950.00
105,618.00
94,466.00
--
Net Income from Continuing & Discontinued Operation
-161,089.00
-119,763.00
-82,508.00
-105,584.00
-93,961.00
--
Normalized Income
-76,191.00
-63,190.00
-82,442.00
-105,584.00
-93,961.00
--
Interest Income
1,959.00
1,372.00
685.00
--
--
--
Net Interest Income
1,959.00
1,372.00
685.00
555.00
559.00
--
EBIT
-78,034.00
-64,535.00
-82,950.00
-105,618.00
-94,466.00
--
EBITDA
-77,668.00
-64,181.00
-82,507.00
-105,203.00
-94,086.00
--
Reconciled Depreciation
366.00
354.00
443.00
415.00
380.00
--
Net Income from Continuing Operation Net Minority Interest
-161,089.00
-119,763.00
-82,508.00
-105,584.00
-93,961.00
--
Total Unusual Items Excluding Goodwill
-84,898.00
-56,573.00
-66.00
--
--
--
Total Unusual Items
-84,898.00
-56,573.00
-66.00
--
--
--
Normalized EBITDA
7,230.00
-7,608.00
-82,441.00
-105,203.00
-94,086.00
--
12/31/2019 - 5/14/2019
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
SNDX Syndax Pharmaceuticals, Inc.
19.16
-1.89%
ANNX Annexon, Inc.
7.57
+1.20%
AUTL Autolus Therapeutics plc
4.4400
-1.77%
PHAT Phathom Pharmaceuticals, Inc.
16.59
+6.89%
RLMD Relmada Therapeutics, Inc.
3.6400
+0.28%
EWTX Edgewise Therapeutics, Inc.
34.42
-1.23%
MRNS Marinus Pharmaceuticals, Inc.
1.7500
-3.85%
VRDN Viridian Therapeutics, Inc.
24.44
-0.53%
RYTM Rhythm Pharmaceuticals, Inc.
49.13
-2.11%
TVTX Travere Therapeutics, Inc.
17.97
-0.72%